… (>15 cm), TASC C and D 14 SFA lesions (the heparin-bonded Viabahn was unavailable in
… with dissected SFA lesions and any previous SFA intervention (eg, angioplasty, stenting, or …

… data on long sfa lesions and supera stenting is mainly based … lesions >15 cm with 53%
CTOs and 52% of the SFA lesions … (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver …

… femoropopliteal lesions, including long lesions, chronic total occlusions, and in-stent restenosis…
been used, including bare-metal stents (BMS), covered stents, atherectomy, drug-eluting …

… Sirolimus Coated Cordis Self-expandable Stent (SIROCCO) study and the Femoral Artery …
led us to conduct a multicenter investigation of their use in SFA lesions where overlap of stents …

… superior results of stents over PTA for short to intermediate-length lesions in the SFA, with
1-year … Despite the benefits of stents, concerns exist regarding the effect of in-stent restenosis, …

… Generally, covered stents were used in lesions with a length of more than 15 cm, whereas
… with a heparin-bonded covered stent for chronic occlusive disease of the SFA. Based on our …

… used Teflon coated dilators to sequentially angioplasty the SFA in an … SFA PTA to Nitinol
stenting in 206 patients [18]. The mean lesion length treated in this study was 7.7cm in the stent …

… supporting primary stenting for intermediate length SFA lesions. The … -covered stent that
has been FDA approved for use in SFA disease. The expanded polytetrafluoroethylene covering …

… Chronic lesions within the SFA tend to be … for SFA stent placement when compared to PTA
alone, in well-matched patient groups, did not support the primary employment of SFA stents, …

… implantations for treatment of SFA lesions less than 13 cm … and TASC C (40.4%) lesions
in 52 patients. Primary patency … roles of bare nitinol stenting and covered stenting in the SFA. …